GlassScriptPhysician profile
Matthew C Farbman
NPI 1124459086
$291,039.03
in general payments reported to CMS, 2019-2025
50 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,412 · 2020: $3,332 · 2021: $14K · 2022: $43K · 2023: $25K · 2024: $62K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Consulting Fee: $27K · Food and Beverage: $26K · Travel and Lodging: $10K · Education: $639 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,447.50 |
| Consulting Fee | $27,430.00 |
| Food and Beverage | $25,627.01 |
| Travel and Lodging | $10,323.72 |
| Education | $639.12 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $94,800.01 | 2019-2025 | Otezla, Otezla, Enbrel |
| Mallinckrodt Hospital Products INC. | $70,647.80 | 2020-2025 | Acthar |
| Ucb, INC. | $45,089.66 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $41,977.13 | 2019-2025 | |
| Horizon Therapeutics Plc | $10,092.48 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $7,068.47 | 2019-2025 | |
| Janssen Biotech, INC. | $6,233.16 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $2,316.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,840.38 | 2019-2025 | Benlysta, Nucala |
| Radius Health, INC. | $1,790.06 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $1,583.16 | 2019-2025 | Orencia |
| Lilly USA, LLC | $1,442.90 | 2019-2025 | Taltz |
| Ucb Sa | $920.00 | 2025 | Bimzelx |
| Genzyme Corporation | $910.18 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $702.11 | 2019-2025 | Saphnelo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Farbman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.